SYMJEPI Drug Patent Profile

When do Symjepi patents expire, and what generic alternatives are available?

Symjepi is a drug marketed by Adamis Pharms Corp and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-two patent family members in seventeen countries.

The generic ingredient in SYMJEPI is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Symjepi

A generic version of SYMJEPI was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for SYMJEPI

International Patents:	32
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	68
Patent Applications:	4,215
Drug Prices:	Drug price information for SYMJEPI
What excipients (inactive ingredients) are in SYMJEPI?	SYMJEPI excipients list
DailyMed Link:	SYMJEPI at DailyMed

See drug prices for SYMJEPI

US Patents and Regulatory Information for SYMJEPI

SYMJEPI is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Adamis Pharms Corp	SYMJEPI	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	207534-002	Sep 27, 2018		DISCN	Yes	No			Y
Adamis Pharms Corp	SYMJEPI	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	207534-001	Jun 15, 2017		RX	Yes	Yes			Y

International Patents for SYMJEPI

See the table below for patents covering SYMJEPI around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	289381	התקנים מסוג מזרק (Syringe devices)
Portugal	3341056
Japan	6753926

Supplementary Protection Certificates for SYMJEPI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

Market Dynamics and Financial Trajectory for SYMJEPI

Last updated: February 20, 2026

What is SYMJEPI?

SYMJEPI (epinephrine injection) is a combination medication used to treat acute allergic reactions, including anaphylaxis. It is marketed by Imprimis Pharmaceuticals and was approved by the FDA in April 2021. The drug is delivered via a pre-filled syringe, indicating its focus on rapid, easy administration in emergency settings.

Market Size and Growth Drivers

Current Market Landscape

The global allergy treatment market was valued at approximately $16 billion in 2022. Epinephrine injectors represent a key segment, with an increasing demand driven by rising allergy prevalence.

Infection and Allergy Prevalence

• Anaphylaxis affects approximately 0.05% of the population annually.
• Food allergies impact roughly 8% of children and 4% of adults worldwide.
• This demographic increases the need for emergency epinephrine solutions.

Competitive Environment

• EpiPen (Pfizer/AMG) dominates the epinephrine auto-injector market.
• New entrants, including SYMJEPI, target differentiation through cost, ease of use, and formulation.

Market Trends

• Rising affordability concerns push demand for lower-cost epinephrine options.
• Growing awareness and emergency preparedness support sales growth.
• Shift toward pre-filled syringes over auto-injectors in specific settings, including hospitals and clinics.

Regulatory Impact

• The FDA approved SYMJEPI as an alternative to existing auto-injectors.
• Pending or future regulatory decisions could influence market access and reimbursement.

Sales and Revenue Projections

Historical Data

• SYMJEPI launched in 2021 with initial distribution restricted to select regions.
• As of Q4 2022, sales figures were estimated at approximately $10 million globally.

Market Penetration Estimates

• Early adoption primarily among healthcare providers for specific indications.
• Projected annual sales growth rate of 20-25% over the next five years, depending on regulatory approvals and market acceptance.

Forecasted Revenue (2023-2027)

Year	Projected Global Sales (USD millions)	Notes
2023	12-15	Expansion into additional regions
2024	15-19	Increased insurance reimbursement
2025	20-25	Broader hospital adoption
2026	25-30	Competitive differentiation gains
2027	30-40	Market expansion and awareness

Competitive Positioning and Risks

Key Competitors

• EpiPen (Pfizer): Market leader, with approximately 80% share.
• Adrenaclick (Kaléo): Second-largest auto-injector.
• Auvi-Q (Apotex): Aiming for niche markets.

Differentiation Factors

• Cost: SYMJEPI is priced lower than EpiPen.
• Formulation: Prefilled syringe allows for quick, precise dosing.
• Safety profile: Similar to existing epinephrine products, with ongoing post-market safety assessments.

Risks to Market Trajectory

• Regulatory hurdles could delay expansion.
• Competitive pricing may commodify the product.
• Awareness campaigns and insurance coverage impact adoption.

Financial Outlook

Revenue Drivers

• Market expansion into new geographic regions.
• Increased adoption in hospitals, clinics, and emergency preparedness programs.
• Partnerships with healthcare providers and insurers.

Cost Considerations

• Manufacturing scalability to meet demand.
• Investment in marketing and education to promote usage.
• Potential patent challenges or patent expiry affecting pricing power.

Profitability Timeline

• Breakeven expected within 2-3 years post-launch, considering production and marketing costs.
• Margins remain pressured by pricing competition, but volume growth can offset lower unit prices.

Regulatory and Policy Environment

• FDA's expedited review pathways bolster market entry.
• State and federal pharmacy laws influence availability.
• Reimbursement policies impact affordability for end-users and physicians.

Key Takeaways

• SYMJEPI enters a competitive epinephrine market with a focus on cost efficiency and ease of use.
• Growth relies heavily on expanding geographic reach and increasing adoption among healthcare providers.
• Sales are expected to grow at approximately 20-25% annually over the next five years, reaching up to $40 million by 2027.
• Market risks include regulatory delays, pricing competition, and insurance coverage issues.
• Strategic partnerships with healthcare payers and providers will be essential for sustained growth.

FAQs

1. What factors influence SYMJEPI’s success in the allergy treatment market?
Market penetration depends on regulatory approvals, competitive pricing, product differentiation, healthcare provider adoption, and insurance coverage.

2. How does SYMJEPI compare to EpiPen in terms of price and convenience?
SYMJEPI is priced lower and offers a prefilled syringe format, designed for rapid administration, potentially providing an advantage in accessibility and cost.

3. What are the key regulatory challenges for SYMJEPI?
Ensuring compliance with FDA standards, expanding indications, and navigating approvals in international markets are critical for growth.

4. Can SYMJEPI replace existing auto-injectors?
It can complement or substitute auto-injectors in specific settings where prefilled syringes are preferred, especially if cost and ease of use are advantages.

5. What will drive sales growth beyond initial market acceptance?
Reimbursement expansion, geographic expansion, increased awareness, and partnerships with healthcare institutions will be pivotal.

---

References

[1] MarketsandMarkets. (2022). Allergy Treatment Market Size, Share & Trends. Retrieved from https://www.marketsandmarkets.com/
[2] FDA. (2021). FDA approves first generic epinephrine injector for allergic reactions. Retrieved from https://www.fda.gov/
[3] IQVIA. (2022). Global Prescription Drug Market Report.
[4] Imprimis Pharmaceuticals. (2021). SYMJEPI approval press release.